Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.43%
SPX
+0.27%
IXIC
+0.37%
FTSE
+0.10%
N225
+0.87%
AXJO
+0.31%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Overview

Loading chart...

Key Stats

Market Cap
62.86B
Dividend Yield
0.00%
P/E Ratio
-197.01
EPS
-2.17
Revenue
2.25B
Avg. Volume
1.38M

Recently from Cashu

publisher logo
Cashu

Alnylam Pharmaceuticals: Leading Innovations in RNA Interference Therapeutics for Genetic Diseases

5 days ago
publisher logo
Cashu

Alnylam Pharmaceuticals: Leading Innovations in RNA Interference and Strong Stock Performance

6 days ago
publisher logo
Cashu

Alnylam Pharmaceuticals: Leading RNAi Therapeutics with Strong Market Performance and Innovation

8 days ago

About

What does ALNY do?
Alnylam Pharmaceuticals, based in Cambridge, Massachusetts, specializes in mRNA cell therapies for autoimmune diseases, with its lead candidate Descartes-08 in Phase IIb trials for generalized myasthenia gravis. The company also develops Descartes-15 and Descartes-33, targeting B cell maturation antigen and autoimmune drivers, respectively.
Sector
💻 Health Care
IPO
CEO
Employees
2,230
Headquarters
Massachusetts, USA
Website
http://www.alnylam.com
Join our newsletter to keep up to date with us!
Stocks
Health Care
alny
Alnylam Pharmaceuticals
NASDAQ: ALNY
+27.38 (+6.02%)
482.41
USD
At close at Sep 09, 20:38 UTC
Summary
News
Signals
Benchmarks
Financials